Amrit Ray M.D., M.B.A.
Chief Patient Officer, Biohaven Pharmaceuticals
Amrit Ray, M.D., M.B.A. joined the Ultragenyx Board in April 2022. He currently serves as Chief Patient Officer for Biohaven Pharmaceuticals, a commercial-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases. Prior to joining Biohaven, he was a Senior Advisor to Bain Capital Life Sciences, which invests in biopharmaceutical, medical device, diagnostics, and technology companies. Previously, Dr. Ray served as Global President, Head of R&D and Medical, and Executive Leadership Team member at Pfizer Upjohn where he oversaw all aspects of research, Phases I-IV development, regulatory, safety and medical affairs worldwide. Dr. Ray chaired the R&D Investment Committee and served as the company’s most senior decision-maker and spokesperson on patient matters. Before Pfizer, Dr. Ray was Chief Medical Officer and R&D Leadership Team Member for pharmaceuticals at Johnson & Johnson.
Dr. Ray earned degrees in Immunology and in Medicine at Edinburgh University, and an MBA at Dartmouth College’s Tuck School. He is a Visiting Professor of Practice at the Faculty of Medical Sciences, Newcastle University, UK, and a board member at the EveryLife Foundation for rare diseases.
Dr. Ray earned degrees in Immunology and in Medicine at Edinburgh University, and an MBA at Dartmouth College’s Tuck School. He is a Visiting Professor of Practice at the Faculty of Medical Sciences, Newcastle University, UK, and a board member at the EveryLife Foundation for rare diseases.